Valuation: Evolus, Inc.

Market Cap 472M 419M 391M 356M 672M 45.34B 679M 4.73B 1.83B 23.18B 1.77B 1.73B 74.38B P/E 2026 *
-14.5x
P/E 2027 * -45.8x
Enterprise Value 593M 527M 491M 448M 845M 56.97B 853M 5.95B 2.3B 29.12B 2.22B 2.18B 93.47B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.52x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -
1 week-8.88%
Current month-10.39%
1 month-18.90%
3 months+5.71%
6 months+82.02%
Current year+15.56%
1 week 6.3
Extreme 6.296
7.12
1 month 6.3
Extreme 6.296
7.96
3 years 3.36
Extreme 3.36
16.1
5 years 3.36
Extreme 3.36
16.1
Manager TitleAgeSince
Chief Executive Officer 48 2018-05-05
Director of Finance/CFO 48 2025-09-07
Chief Operating Officer - 2022-08-31
Director TitleAgeSince
Chairman 63 2017-12-31
Director/Board Member 71 2018-02-11
Director/Board Member 48 2018-05-05
Change 5-day change 1-year change 3-year change Capi.($)
-7.55%-8.88%+19.96%-23.66% 472M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.23%-3.39%+26.45%+49.07% 410.8B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.94%

Financials

2026 *2027 *
Net sales 334M 297M 277M 253M 476M 32.12B 481M 3.35B 1.3B 16.42B 1.25B 1.23B 52.7B 392M 348M 325M 296M 559M 37.7B 564M 3.94B 1.53B 19.27B 1.47B 1.44B 61.86B
Net income -31.58M -28.06M -26.19M -23.87M -45.01M -3.04B -45.43M -317M -123M -1.55B -119M -116M -4.98B -9.05M -8.04M -7.5M -6.84M -12.9M -870M -13.02M -90.8M -35.18M -445M -33.97M -33.23M -1.43B
Net Debt 121M 108M 100M 91.46M 172M 11.63B 174M 1.21B 471M 5.95B 454M 444M 19.08B 126M 112M 104M 95.24M 180M 12.11B 181M 1.26B 490M 6.19B 473M 463M 19.87B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
-
Date Price Change
26-10-02 €6.298 -7.55%
26-10-01 €6.812 -3.07%
26-09-30 €7.028 +0.34%
26-09-29 €7.004 +0.98%
26-09-28 €6.936 +0.35%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.140USD
Average target price
15.00USD
Spread / Average Target
+110.08%

Quarterly revenue - Rate of surprise